Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Voyager Therapeutics (VYGR) over the last 10 years, with Q3 2025 value amounting to $58.8 million.

  • Voyager Therapeutics' Shares Outstanding (Weighted Average) rose 164.54% to $58.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.8 million, marking a year-over-year increase of 164.54%. This contributed to the annual value of $35.9 million for FY2019, which is 1195.19% up from last year.
  • Voyager Therapeutics' Shares Outstanding (Weighted Average) amounted to $58.8 million in Q3 2025, which was up 164.54% from $58.7 million recorded in Q2 2025.
  • Voyager Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $58.8 million during Q3 2025, with a 5-year trough of $37.5 million in Q1 2021.
  • Over the past 4 years, Voyager Therapeutics' median Shares Outstanding (Weighted Average) value was $57.4 million (recorded in 2024), while the average stood at $50.0 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first skyrocketed by 145.5% in 2021, then skyrocketed by 215.82% in 2025.
  • Voyager Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $37.6 million in 2021, then grew by 1.91% to $38.3 million in 2022, then soared by 51.05% to $57.9 million in 2024, then rose by 1.65% to $58.8 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $58.8 million for Q3 2025, versus $58.7 million for Q2 2025 and $58.3 million for Q1 2025.